Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:
In December, Vertex Pharmaceuticalsannounced results from a mid-stage clinical trial showing its experimental, non-opioid drug reduced pain in people with diabetes who have chronic pain. This quarter, the company will read out results from Phase 3 studies of the same pain drug, called VX-548, in people with acute pain following surgery.
advertisement
The next big test of Alnylam Pharmaceuticals’pipeline of RNA-interference medicines looms with the outcome of a Phase 3 study called HELIOS-B that is investigating vutrisiran as a treatment for ATTR-CM, a progressive disease that leads to heart failure.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+
Next article： How one medical school became remarkably diverse
Next article： How one medical school became remarkably diverse
